Murine Oncogenicity and Pharmacokinetics Studies of 9-cis-UAB30, an RXR Agonist, for Breast Cancer Chemoprevention
- 24 March 2010
- journal article
- research article
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 29 (2) , 157-164
Abstract
The synthetic retinoic acid analog, 9- cis-UAB30 [(2E,4E,6Z,8E)-8-(3′,4′-dihydro-1′(2′H)-naphthalen-1′-ylidene)-3,7-dimethyl-2,4,6-octatrienoic acid], is a specific ligand for the retinoid X receptor. Murine oncogenicity and pharmacokinetics studies were performed as part of the preclinical development of 9- cis-UAB30 for breast cancer chemoprevention. In the oncogenicity study, TSG-p53(+/-) (p53 knockout) mice (25 per sex per group) received daily gavage exposure to 9- cis-UAB30 doses of 0 (control), 30, 100, or 300 mg/kg/d for 6 months. Positive controls received p-cresidine (400 mg/kg/d) for 6 months. 9- cis-UAB30 had no biologically significant effects on survival, body weight, body weight gain, clinical signs, hematology, or clinical chemistry but induced dose-related hepatomegaly in both sexes and decreased thymus weights in high-dose females. Gross and microscopic pathology provided no evidence of 9- cis-UAB30 toxicity or oncogenicity; by contrast, p-cresidine induced urinary bladder neoplasms in more than 60% of male and female mice. It was concluded that 9- cis-UAB30 is not oncogenic in p53(+/-) mice. In the pharmacokinetics study, C57BL/6 mice received daily gavage exposure to 9- cis-UAB30 (100 or 300 mg/kg/d) for 1 or 7 days. Pharmacokinetic parameters were similar after 1 and 7 days of dosing. Dose-related peak plasma levels of 9- cis-UAB30 were seen between 0.25 and 3 hours; volume of distribution was comparable at both dose levels. Increases in area under the curve were less than proportional to dose and were associated with an increased rate of apparent clearance and decreased elimination half-life. These results suggest decreased absorption and/or possible induction of clearance mechanisms. Enzyme induction may underlie the hepatomegaly seen in mice treated with 9- cis-UAB30 for 6 months in the oncogenicity study.Keywords
This publication has 23 references indexed in Scilit:
- Sex Differences in the Expression of Hepatic Drug Metabolizing EnzymesMolecular Pharmacology, 2009
- Therapeutic Potential of “Rexinoids” in Cancer Prevention and TreatmentCancer Research, 2009
- Temporal Evaluation of CYP mRNA in Mice Administered with Prototypical P450 Inducers: Comparison with Conventional Protein/Enzyme MethodsDrug and Chemical Toxicology, 2008
- Subchronic Toxicity and Toxicogenomic Evaluation of Tamoxifen Citrate + Bexarotene in Female RatsToxicological Sciences, 2007
- In Vitro Metabolic Characterization, Phenotyping, and Kinetic Studies of 9cUAB30, a Retinoid X Receptor-Specific RetinoidDrug Metabolism and Disposition, 2007
- Oncogenicity Evaluations of Chemopreventive Soy Components in p53(+/–) (p53 knockout) MiceInternational Journal of Toxicology, 2006
- Clinical trials with retinoids for breast cancer chemopreventionEndocrine-Related Cancer, 2006
- The Utility of Genetically Modified Mouse Assays for Identifying Human Carcinogens: A Basic Understanding and Path ForwardToxicological Sciences, 2004
- Testing for the equality of area under the curves when using destructive measurement techniquesJournal of Pharmacokinetics and Biopharmaceutics, 1988
- Anticarcinogenic effect of retinoids on 7,12-dimethylbenz(a)anthracene-induced mammary tumor induction, and its relationship to cyclic AMP-dependent protein kinaseBiochemical and Biophysical Research Communications, 1986